SGLT-2 inhibitors in Heart Failure

Cardio-Ed

English - June 08, 2021 09:00 - 34 minutes - 23.7 MB - ★★★★★ - 1 rating
Medicine Health & Fitness cardiology interventional cardiology echocardiography clinical trials medicine structural heart disease heart failure arrhythmia myocardial infarction cardiomyopathy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: COVID-19 Vaccine Associated Thrombosis

Next Episode: Role of SGLT-2 inhibitors in Heart Failure with reduced ejection fraction

SGLT2 inhibitors, the novel anti-diabetics are the new drugs which which have been approved for heart failure with reduced ejection fraction (HFrEF).
After the landmark EMPA-REG_OUTCOME, DECLARE TIM IN 58, EMPEROR REDUCED and DAPA HF trials, empagliflozin and dapagliflozin have found a place in the management of HFrEF or heart failure.
Lets discover what makes them special drugs in heart failure.